ReviewNaunyn-Schmiedeberg's archives of pharmacology2025
A comprehensive review on liraglutide and novel nanocarrier-based systems for the effective delivery of liraglutide.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Liraglutide Promoted Osteogenic Differentiation of Dental Pulp Stem Cells via H3K18 Lactylation-Dependent DSPP Activation.Tissue engineering and regenerative medicine · 2026Article
- Crosstalk between ferroptosis and miRNA in type 2 diabetes mellitus and possible therapeutic targeting.European journal of medical research · 2025Review
- Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases.Journal of nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glucagon-like peptide-1 (GLP-1) analogs are synthetic derivatives of the natural incretin hormone GLP-1, which plays a crucial role in glucose metabolism. These analogs mimic the function of endogenous GLP-1 by stimulating insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety, making them effective for managing type 2 diabetes mellitus (T2DM) and obesity. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, has gained considerable attention for its potential in treating type 2 diabetes mellitus, obesity, and cardiovascular disorders. However, its therapeutic application is significantly hindered by poor absorption, a short biological half-life, and unintended off-target effects, necessitating advanced drug delivery strategies. To address these challenges, various nanocarrier-based systems-such as nanofibers, liposomes, polymeric nanoparticles, exosomes, hydrogels, and lipid nanoparticles-have been explored. These nanocarriers facilitate site-specific and sustained release of liraglutide, improving its bioavailability and therapeutic efficacy. This article provides a comprehensive overview of liraglutide's pharmacological properties, preclinical studies, and the potential of different nanocarrier-based approaches in optimizing its delivery for enhanced clinical outcomes.
Indexed as
Identifiers
40014122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.